Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Identifying Predictors of Poor Health-Related Quality-of-Life among Pediatric Hematopoietic Stem Cell Donors.

Pediatrics

Pediatrics
N/A
Kitko, Carrie
NCT03718546
VICCPED1949

Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository

Miscellaneous

Miscellaneous
N/A
Kitko, Carrie
VICCPED1544

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Multiple Cancer Types

The purpose of the study is to assess the efficacy and safety of tisagenlecleucel in children and adolescents with relapsed / refractory B-cell non-Hodgkin lymphoma (r / r B-NHL). For pediatric patients who have r / r B-NHL, survival rates are dismal, only ~20-50% subjects are alive at 2 years with overall response rate (ORR) of 20-30% after conventional salvage chemotherapy.
Pediatric Lymphoma, Pediatrics
II
Kitko, Carrie
NCT03610724
VICCPED18169

KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL / AML / MDS Allo-HCT Children

Multiple Cancer Types

This is a phase II, open-label, non-randomized, prospective study of haploidentical transplantation using KIR-favorable donors for children with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). The relationship of KIR2DL1 polymorphisms to survival in children with these diseases undergoing any approach to allogeneic HCT during the study time frame will also be determined.
Myelodysplastic Syndrome, Pediatric Leukemia, Pediatrics
II
Kitko, Carrie
NCT02646839
VICCPED1711

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: